Allergan’s unusual arrangement to try to avoid IPR proceedings on Restasis made headlines last week. Our article suggesting the move is potentially damaging for the image of the biopharma sector as a whole prompted a response from Acorda CEO Ron Cohen.
Allergan PLC’s transfer of patent rights on Restatis to the St. Regis Mohawk tribe has brought renewed attention to the biopharma industry’s concerns about the inter partes review (IPR) patent review process.
In an earlier article, we offered a view that Allergan’s move is likely to backfire, at least if the broader goal is to improve the public policy climate
The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.
Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.
The mood at the World Vaccines Congress in Washington, D.C. was bleak given Robert F. Kennedy Jr.’s rise to lead the Trump Administration’s Health and Human Services Department, but vaccine lawyers offered an optimistic outlook and ideas for countering his vaccine agenda.
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.
Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.
England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.
The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.
